SCHEMBL23705343

SCHEMBL23705343

Cc1cc(C(=O)O)cc(C(C)(C)CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.42
HCAR1 Q9BXC0 1/20 0.38
MAPT P10636 2/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
BRD4 O60885 1/20 0.35
KDM4A O75164 1/20 0.34
SERPINE1 P05121 1/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
POLB P06746 1/20 0.34
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23704861 0.81 NPC1 (0.43) MAPTRXRARXRBMRGPRX4BRD4
SCHEMBL30058882 0.81 NPC1 (0.43) MAPTRXRARXRBMRGPRX4BRD4
SCHEMBL6211950 0.80 MAPT (0.49) MAPTRXRARXRBMEN1KMT2A
SCHEMBL4134700 0.76 NPC1 (0.38) MEN1KMT2AGAAKDM4ASERPINE1
SCHEMBL23704950 0.76 MAPT (0.42) MAPTTSHRMEN1KMT2AGAA
SCHEMBL630419 0.75 IDO1 (0.47) MEN1KMT2AGAAKDM4ACA1
SCHEMBL16533934 0.74 CA12 (0.51) TPMTMAPTALDH1A1TSHRMEN1
SCHEMBL16533942 0.73 CA12 (0.52) ALDH1A1MEN1KMT2AGAABRD4
SCHEMBL25923116 0.73 TPMT (0.48) TPMTHCAR1MAPTMEN1KMT2A
SCHEMBL23704882 0.72 MDH1 (0.45) TSHRMRGPRX4BRD4KDM4APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB TPMT 463/4885HCAR1 4259/4885MAPT 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.